Daiichi Sankyo And AstraZeneca's Enhertu Shows Significant PFS Improvement As First-Line HER2 Mutant NSCLC Treatment In DESTINY-Lung04 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this settingData to be presented at an
Enhertu, a medicine made by two companies, worked really well in a big test against a common type of lung cancer. This is good news that shows the medicine might help more patients, so people will watch to see if doctors start using it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.